Cargando…
Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway
TNF-related apoptosis-inducing ligand (TRAIL) is a tumor-selective apoptosis inducer and has been shown to be promising for treating various types of cancers. However, the application of TRAIL is greatly impeded by the resistance of cancer cells to its action. Studies show that overexpression of som...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178493/ https://www.ncbi.nlm.nih.gov/pubmed/25257790 http://dx.doi.org/10.3390/md12095072 |
_version_ | 1782336965372280832 |
---|---|
author | Liu, Jia Ma, Leina Wu, Ning Liu, Ge Zheng, Lanhong Lin, Xiukun |
author_facet | Liu, Jia Ma, Leina Wu, Ning Liu, Ge Zheng, Lanhong Lin, Xiukun |
author_sort | Liu, Jia |
collection | PubMed |
description | TNF-related apoptosis-inducing ligand (TRAIL) is a tumor-selective apoptosis inducer and has been shown to be promising for treating various types of cancers. However, the application of TRAIL is greatly impeded by the resistance of cancer cells to its action. Studies show that overexpression of some critical pro-survival proteins, such as survivin, is responsible for TRAIL resistance. In this study, we found that Aplysin, a brominated compound from marine organisms, was able to restore the sensitivity of cancer cells to TRAIL both in vitro and in vivo. Aplysin was found to enhance the tumor-suppressing capacity of TRAIL on several TRAIL-resistant cancer cell lines. TRAIL-induced apoptosis was also potentiated in A549 and MCF7 cells treated with Aplysin. Survivin downregulation was identified as a mechanism by which Aplysin-mediated TRAIL sensitization of cancer cells. Furthermore, the activation of p38 MAPK was revealed in Aplysin-treated cancer cells, and its inhibitor SB203580 was able to abrogate the promoting effect of Aplysin on the response of cancer cells to TRAIL action, as evidenced by restored survivin expression, elevated cell survival and reduced apoptotic rates. In conclusion, we provided evidence that Aplysin acts as a sensitizer for TRAIL and its effect on p38 MAPK/survivin pathway may partially account for this activity. Considering its low cytotoxicity to normal cells, Aplysin may be a promising agent for cancer treatment in combination with TRAIL. |
format | Online Article Text |
id | pubmed-4178493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-41784932014-10-02 Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway Liu, Jia Ma, Leina Wu, Ning Liu, Ge Zheng, Lanhong Lin, Xiukun Mar Drugs Article TNF-related apoptosis-inducing ligand (TRAIL) is a tumor-selective apoptosis inducer and has been shown to be promising for treating various types of cancers. However, the application of TRAIL is greatly impeded by the resistance of cancer cells to its action. Studies show that overexpression of some critical pro-survival proteins, such as survivin, is responsible for TRAIL resistance. In this study, we found that Aplysin, a brominated compound from marine organisms, was able to restore the sensitivity of cancer cells to TRAIL both in vitro and in vivo. Aplysin was found to enhance the tumor-suppressing capacity of TRAIL on several TRAIL-resistant cancer cell lines. TRAIL-induced apoptosis was also potentiated in A549 and MCF7 cells treated with Aplysin. Survivin downregulation was identified as a mechanism by which Aplysin-mediated TRAIL sensitization of cancer cells. Furthermore, the activation of p38 MAPK was revealed in Aplysin-treated cancer cells, and its inhibitor SB203580 was able to abrogate the promoting effect of Aplysin on the response of cancer cells to TRAIL action, as evidenced by restored survivin expression, elevated cell survival and reduced apoptotic rates. In conclusion, we provided evidence that Aplysin acts as a sensitizer for TRAIL and its effect on p38 MAPK/survivin pathway may partially account for this activity. Considering its low cytotoxicity to normal cells, Aplysin may be a promising agent for cancer treatment in combination with TRAIL. MDPI 2014-09-25 /pmc/articles/PMC4178493/ /pubmed/25257790 http://dx.doi.org/10.3390/md12095072 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Liu, Jia Ma, Leina Wu, Ning Liu, Ge Zheng, Lanhong Lin, Xiukun Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway |
title | Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway |
title_full | Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway |
title_fullStr | Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway |
title_full_unstemmed | Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway |
title_short | Aplysin Sensitizes Cancer Cells to TRAIL by Suppressing P38 MAPK/Survivin Pathway |
title_sort | aplysin sensitizes cancer cells to trail by suppressing p38 mapk/survivin pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178493/ https://www.ncbi.nlm.nih.gov/pubmed/25257790 http://dx.doi.org/10.3390/md12095072 |
work_keys_str_mv | AT liujia aplysinsensitizescancercellstotrailbysuppressingp38mapksurvivinpathway AT maleina aplysinsensitizescancercellstotrailbysuppressingp38mapksurvivinpathway AT wuning aplysinsensitizescancercellstotrailbysuppressingp38mapksurvivinpathway AT liuge aplysinsensitizescancercellstotrailbysuppressingp38mapksurvivinpathway AT zhenglanhong aplysinsensitizescancercellstotrailbysuppressingp38mapksurvivinpathway AT linxiukun aplysinsensitizescancercellstotrailbysuppressingp38mapksurvivinpathway |